EFFECT OF LETROZOLE ON BONE MARKERS AND BLOOD PRESSURE

来曲唑对骨标志物和血压的影响

• 批准号: 7377352
• 负责人: PAMELA TAXEL
• 金额: $ 0.4万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377352
• 关键词: EFFECT; LETROZOLE; BONE; MARKERS; BLOOD

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Studies using aromatase inhibitors (AI) have recently demonstrated improved disease free survival after five years of tamoxifen therapy for early stage breast cancer in postmenopausal women. AI are a class of compounds that inhibit the synthesis of estrogens from androgens by blocking aromatase, a cytochrome P450 enzyme, which catalyses the peripheral conversion of androgens to estrogens, thereby reducing the tissue and plasma concentration of estradiol to below castrate levels. We hypothesize that with suppression of estradiol, letrozole, the most potent aromatase inhibitor, will cause a significant increase in markers of bone resorption and bone formation, along with an increase in baseline blood pressure and loss of nocturnal dipping of blood pressure. The following specific aims will be studied: To determine the effects of letrozole on sex hormone levels and the relationship of change in sex hormone levels to the change in bone markers. To determine the change in markers of bone resorption and formation. To examine the effects of letrozole on 24 hr ambulatory blood pressure monitoring and office blood pressure. To determine change in parameters of neurocognitive function with letrozole therapy. This will be a 12 week, open label pilot study evaluating women with primary breast cancer, who have completed five years of tamoxifen treatment and are opting to choose letrozole as treatment in consultation with their oncologist. The patients will serve as their own controls.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。使用芳香化酶抑制剂（AI）的研究最近表明，绝经后妇女的早期乳腺癌患者在接受他莫昔芬治疗5年后，无病生存率有所提高。AI是一类通过阻断芳香酶（一种细胞色素P450酶，其催化雄激素向雌激素的外周转化）来抑制雄激素合成雌激素的化合物，从而将雌二醇的组织和血浆浓度降低至低于去势水平。 我们假设，在抑制雌二醇的情况下，来曲唑（最有效的芳香酶抑制剂）将导致骨吸收和骨形成标志物显着增加，同时沿着基线血压升高和夜间血压下降的消失。将研究以下具体目的：确定来曲唑对性激素水平的影响以及性激素水平变化与骨标志物变化的关系。 确定骨吸收和形成标志物的变化。观察来曲唑对24小时动态血压和诊室血压的影响。来曲唑治疗后神经认知功能参数的变化。 这将是一项为期12周的开放标签试点研究，评估已完成5年他莫昔芬治疗并在与肿瘤学家协商后选择来曲唑作为治疗的原发性乳腺癌女性。患者将作为自己的对照。